Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants

Citation
M. Pezzati et al., Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants, EUR J PED, 160(9), 2001, pp. 572-575
Citations number
25
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pediatrics,"Medical Research General Topics
Journal title
EUROPEAN JOURNAL OF PEDIATRICS
ISSN journal
0340-6199 → ACNP
Volume
160
Issue
9
Year of publication
2001
Pages
572 - 575
Database
ISI
SICI code
0340-6199(200109)160:9<572:RCTOTE>2.0.ZU;2-X
Abstract
In this study we determined the effects of cisapride on the pyloric muscle in preterm. infants. To perform a randomised, double blind, placebo control led study, two groups each of 16 preterm newborns were given either cisapri de (0.2 mg/kg every 8 h) or a placebo for at least 7 days. Infants were stu died first on the day when treatment with cisapride or placebo was to be in itiated (time 0), and then after 3 (time 1) and 7 days (time 2). In each gr oup, the following parameters were studied by ultrasonography: cross-sectio nal diameter of the entire pylorus, muscle thickness, and length of the pyl oric canal. Also, the mean daily total gastric aspirate volume was studied for the entire week of the study. At time 0, we observed no significant dif ferences between the two groups with respect to diameter, muscle thickness and length of the pyloric muscle. At time 1 and time 2, both diameter and m uscle thickness were significantly greater in the cisapride group than in t he placebo group. Furthermore, the length of the pyloric canal was signific antly greater in the cisapride group than in placebo group at time 2, thoug h not so at time 1. For the entire week of the study, we found a significan tly larger mean daily total gastric aspirate volume in the group of infants treated with cisapride compared to the placebo treated group. Conclusion: Cisapride significantly affects all of the main measurements of the pyloric muscle and causes a significantly larger amount of daily total gastric asp irate volume. Its use to promote feeding intolerance in preterm newborns ca nnot be recommended.